Biotechinfo.fr, the biotechnology newsletter, interviewed Martine Jandrot-Perrus and Philippe Billiald about the promising development of Acticor’s product for ischemic stroke.

Acticor Biotech, a new biotechnology company entirely dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes is opening its capital to crowdfunding. More details about the company.